ESPR - Esperion - taking on the Statin market

I realize this thread has gotten long.

So here is a summary:

  • CLEAR Outcomes Trial (2023–2024)

    • Mar 2023: Topline results — 13% MACE-4 reduction.

    • Late 2023: Full data presented.

    • Mar 2024: U.S. label update — CV risk reduction.

    • Aug 2025: ESC/EAS Level 1a recommendation.

  • Commercial Progress (U.S.)

    • 2020: Initial launch (LDL-C only).

    • 2024–2025: Post-label growth +42% H1 2025 prescriptions.

    • Payer access: >90% commercial, >80% Medicare.

    • Dec 2025: ACC PAD/Diabetes statement — first-line for LDL-C + limb benefits.

  • Global Expansion & Tech Transfer

    • Europe (Daiichi Sankyo): NILEMDO/NUSTENDI since 2020; Jan 2024 tech transfer announced — DSE assumes manufacturing responsibility (reduces Esperion COGS long-term).

    • Japan (Otsuka): Nov 2025 launch + $90M milestone; future manufacturing transition expected (similar cost relief).

    • Inventory build: Q3 2025 ~$108M net (up from $94M YE2024) — proactive scaling for U.S. demand + partner supply agreements; expected drawdown post-transfers (lower COGS 2027+).

  • Cost Optimizations / OpEx

    • OpEx trajectory: ~$160M annual run-rate 2024–2025; assumption cap $300M total (SG&A + R&D + COGS) from 2026 (breakeven inflection).

    • Tech transfers (Europe 2024, Japan future): Shift manufacturing burden to partners → COGS reduction ~$20–40M/year long-term.

    • Inventory management: Build for growth/partner bulk sales; post-transfer → lower carrying costs, improved margins.

  • IP / Exclusivity

    • ANDA settlements 2025: Generics barred to April 2040.

    • Alkem litigation ongoing.

    • Japan patent granted 2025: Triple combo protection.

  • Debt / Balance Sheet

    • June 2024: $304.7M OMERS DSE royalty sale.

    • Dec 2024: $150M Athyrium loan + $100M 2030 converts.

    • Nov 2025: $55M 2025 notes paid off.

    • Current debt: $250M.

    • Cash ~$197M; runway 2027+.

  • Dilution Summary

    • Shares basic: ~118M YE2023 → ~195M YE2024 → ~205M Q3 2025.

    • Major: Jan 2024 30M offering; Oct 2025 30M shares ($70M net).

    • Fully diluted: ~275M (warrants 26M @ $1.55, 2030 converts 32M, options/RSUs ~17M).

    • Forward expectation: Minimal new dilution post-2026 (FCF covers ops); potential warrant exercises cash-accretive.

  • Investor Communications (Outside Quarterly ERs)

    • Apr 2025: R&D Day (pipeline focus, ESP-2001 nomination).

    • Jan 2025: JP Morgan Healthcare Conference presentation.

    • Nov 2025: Jefferies London Healthcare Conference (CFO remarks on debt payoff).

    • Regular: Firesides at Cowen, Cantor, Needham (2024–2025 dates scattered Q1–Q3).

  • Bempedoic Acid Additional Data

    • 2022: Preclinical ADPKD cyst inhibition.

    • 2025: AHA — VTE/monotherapy subsets.

    • Dec 2025: ACC PAD limb benefits.

  • Next-Gen ACLY Pipeline

    • Apr 2025: R&D Day — ESP-2001 PSC nomination.

    • Oct 2025: IND-enabling PSC; goal IND 2026.

    • Kidney: Preclinical 2022 + Phase 2 completed; BEAT-PKD (DoD) not yet recruiting.

    • Oncology: No direct activity (Espervita separate).

  • Current Snapshot (Dec 19, 2025)

    • Market cap ~$900M.

    • Breakeven 2026 trajectory.

    • Triple combo development ongoing.

5 Likes